Moved to Canada in 1972 to build the first API antibiotic plant in Canada. In 1973, Luciano founded ACIC and masterminded the Corporation’s evolution from distribution to research and development, as well as manufacturing in both APIs and Pharmaceuticals for the pharmaceutical industry worldwide. Luciano was one of the founders of the Canadian Drug Manufacturers’ Association (CDMA) and served as Chairman for three and a half years from 1985-1988. Luciano is also a founding member of the US GPhA (now AAM) and recently received the life achievement award from the GPhA (now AAM) in 2022 or 2023?  One of Luciano’s assets for his international suppliers and clients is his knowledge of multiples languages.

Andrew Gall is the Chief Financial Officer of the ACIC group of entities. With over 25 years of experience from senior executive roles, Andrew has a demonstrated and substantial track record of driving both strategy and financial operations. He has successfully and routinely turned around underperforming organizations, rolled out highly successful new products and services, and driven mergers, operational transformations, and well-received change management initiatives. Andrew has more than 2 decades of experience in mergers, change management, general management, finance, business development, strategy, risk management, legal, governance, information technology, and human resources. In addition to holding an Executive MBA from University of Toronto and an Honours BBA from Wilfrid Laurier University, Andrew is a Fellow Chartered Professional Accountant (FCPA, FCMA), Chartered Director (C. Dir.).

Chris Rayfield has been a valued member of the ACIC Pharmaceuticals team for almost 30 years. He has held various positions within the company of increasing responsibility and currently serves as President of the organization overseeing the Sales and Marketing. Chris is a past Board member of GPhA (now AAM) which is the Generic Pharmaceutical Association Advocacy Group in the USA and also served 3 terms as a Board of Director and Executive Committee Member of DCAT (Drug Chemical and Associated Technology) which is a business development and Trade Organization based on the USA. Chris received his Diploma in Business Administration, Marketing from Sheridan College then went on to receive a Degree of Bachelor of Administration, General Management in 1995 from Lakehead University.

Bart Grochowski is the Vice President of Sales at ACIC Pharmaceuticals, Inc. Bart brings a wealth of experience in the pharmaceutical industry with over 20 years in business development and commercial sales roles in the United States and in Europe. Bart has a multidisciplinary background in Biochemistry, Molecular Biology, Biotechnology, and Informatics. He holds a Bachelor of Science degree in Biochemistry from Stevens Institute of Technology in Hoboken, NJ and earned his M.S. in Bioinformatics at the University of Sciences in Philadelphia. Bart has completed a Lean Six Sigma certification and has a vast knowledge of science and applied statistics. Bart has lived in United States and Europe throughout his career.

William Nightingale is the Vice President of Business Development at ACIC Pharmaceuticals, Inc. with over 30 years experience working with API and finished dosage form manufacturers, as well as service providers, within the pharmaceutical industry. William brings a vast knowledge and experience, with an undergraduate degree from UofT and an MBA from Wilfred Laurier University.

Sarah Hoogmoed brings over 11 years of dedicated service and expertise to her role as Vice President of Scientific Affairs at ACIC Pharmaceuticals Inc. Sarah’s journey in the pharmaceutical sector began with a strong academic foundation in pharmaceutical sciences, culminating in a Master’s degree in Regulatory Affairs and Quality Assurance from Temple University. This educational background, coupled with her hands-on experience, has equipped her with a comprehensive understanding of regulatory frameworks and quality standards critical to the industry. Under Sarah’s stewardship, the Scientific Affairs division has thrived, achieving milestones in product development and regulatory compliance. Sarah holds a deep-seated belief in the power of science to transform lives and remains committed to upholding the highest standards of integrity and ethical conduct in all scientific endeavors.